EUROPEAN SCALABILITY CONSIDERATIONS TO INDUSTRIALISE EARLY ACADEMIC TRANSLATION

31 Aug 2022
11:00
SPONSORED BY
Exothera SA

11:00 – CHAIR INTRODUCTION

Chair: Stephen Sullivan, Program Manager & International Liaison Officer, GAiT

 

11:05 – FIRESIDE CHAT

Speakers:

Mustafa Munye, Director R&D Operations, Complement Therapeutics

Jenny Prange, Head of GMP Production, Chief Scientific Officer & Co-Founder, MUVON Therapeutics

Edward Samuel, EVP Technical Operations, Achilles Therapeutics

 

11:30 – CASE STUDY: AI-POWERED PRECISION TIL THERAPY

Speaker: Edward Samuel, EVP Technical Operations, Achilles Therapeutics 

 

11:45 – CASE STUDY: FAST TRANSFER OF FLASK-BASED MANUFACTURING TO SCALE-X FIXED-BED BIOREACTOR

Speaker: Hanna P. Lesch, Chief Technology Officer, Exothera 

 

12:00 – CASE STUDY: THE TWO WORLDS OF ACADEMIA AND INDUSTRY COMING TOGETHER AS ONE TEAM 

Speaker: Sofia Hakansson Buch, Vice President for Cell Therapy CMC, Novo Nordisk 

 

12:15 – SPEAKER Q&A

Speakers:

Edward Samuel, EVP Technical Operations, Achilles Therapeutics 

Hanna P. Lesch, Chief Technology Officer, Exothera 

Sofia Hakansson Buch, Vice President for Cell Therapy CMC, Novo Nordisk 

Speakers

Stephen Sullivan
Programme Manager & International Liason Officer
GAiT
Mustafa Munye
Director R&D Operations
Complement Therapeutics
Jenny Prange
CSO and Co-Founder
Muvon Therapeutics
Edward Samuel
EVP Technical Operations
Achilles Therapeutics
Sofia Hakansson Buch
Vice President for Cell Therapy CMC
Novo Nordisk